Novel derivatives of aclacinomycin A block cancer cell migration through inhibition of farnesyl transferase

Shigeyuki Magi, Tetsuo Shitara, Yasushi Takemoto, Masato Sawada, Mitsuhiro Kitagawa, Etsu Tashiro, Yoshikazu Takahashi, Masaya Imoto

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


In the course of screening for an inhibitor of farnesyl transferase (FTase), we identified two compounds, N-benzyl-aclacinomycin A (ACM) and N-allyl-ACM, which are new derivatives of ACM. N-benzyl-ACM and N-allyl-ACM inhibited FTase activity with IC 50 values of 0.86 and 2.93 μM, respectively. Not only ACM but also C-10 epimers of each ACM derivative failed to inhibit FTase. The inhibition of FTase by N-benzyl-ACM and N-allyl-ACM seems to be specific, because these two compounds did not inhibit geranylgeranyltransferase or geranylgeranyl pyrophosphate (GGPP) synthase up to 100 μM. In cultured A431 cells, N-benzyl-ACM and N-allyl-ACM also blocked both the membrane localization of H-Ras and activation of the H-Ras-dependent PI3K/Akt pathway. In addition, they inhibited epidermal growth factor (EGF)-induced migration of A431 cells. Thus, N-benzyl-ACM and N-allyl-ACM inhibited EGF-induced migration of A431 cells by inhibiting the farnesylation of H-Ras and subsequent H-Ras-dependent activation of the PI3K/Akt pathway.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalJournal of Antibiotics
Issue number3
Publication statusPublished - 2013 Mar
Externally publishedYes


  • aclacinomycin A
  • cancer cell migration
  • farnesyl transferase

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Novel derivatives of aclacinomycin A block cancer cell migration through inhibition of farnesyl transferase'. Together they form a unique fingerprint.

Cite this